STING Agonist-1 G10| CAS 702662-50-8

Cas No.:	702662-50-8
Chemical Name:	STING agonist-1
Synonyms:	STING agonist-1;G10;G10 [PMID: 26646986];4-(2-chloro-6-fluorobenzyl)-N-(furan-2-ylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide;GTPL9206;HMS1621G10;BCP33022;s8954;4-[(2-chloro-6-fluorophenyl)methyl]-N-(furan-2-ylmethyl)-3-oxo-1,4-benzothiazine-6-carboxamide;Q27077760;4-[(2-Chloro-6-fluorophenyl;CDB66250;D83678;A918021
SMILES:	ClC1=C([H])C([H])=C([H])C(=C1C([H])([H])N1C(C([H])([H])SC2C([H])=C([H])C(C(N([H])C([H])([H])C3=C([H])C([H])=C([H])O3)=O)=C([H])C1=2)=O)F
Formula:	C₂₁H₁₆ClFN₂O₃S
M.Wt:	430.8797
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

STING agonist-1 (G10) is a novel human-specific STING agonist that elicits antiviral activity against emerging Alphaviruses. G10 potently blocks replication of Alphavirus species Venezuelan Equine Encephalitis Virus (VEEV) (IC90 = 24.57 μM).

In Vitro:

G10 does not bind to STING directly, however, G10 represents the first synthetic small molecule characterized as an indirect activator of human STING-dependent phenotypes.100 μM G10 (a concentration over twelve times the IC90 for CHIKV and over four times the IC90 for VEEV). G10 induces IFN/IRF3- but not NF-κB-dependent transcription in human fibroblasts. G10 Induces IFN/IRF3- but not NF-κB-Dependent Transcription in Human Fibroblasts. G10 activates IRF3, but not canonical NF-κB pathways in human fibroblasts. G10 elicits antiviral activity against New and Old World Alphaviruses. G10 stimulates phosphorylation of IFN regulatory factor 3 (IRF3) in a manner similar to that triggered by UV-inactivated cytomegalovirus (UV-CMV) and Sendai virus (SeV). G10 induces synthesis and secretion of bioactive type I and III IFNs and generates an antiviral state in fibroblast cells positive for STING, IRF3, and STAT1 proteins. G10 triggers innate immune responses that involve expression of IRF3-dependent genes including type I and III interferons.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.

STING Agonist-1(G-10)